340B Duplicate Discounts
Where most engagements begin, and the most measurable.
Prepared for Ajanta Pharma USA Inc.
The Greatest Gross-to-Net Opportunities Are Often the Ones You Can't See
CiiTA helps pharmaceutical manufacturers identify, quantify, prevent, and recover hidden pharmacy-related revenue leakage.
Schedule a Conversation →
30 minutes · No presentation
Confidential and collaborative. Nothing is shared outside this conversation.
Your Estimated Exposure
$4.2M
Estimated annual pharmacy-related revenue leakage at Ajanta Pharma USA Inc.
Derived from Ajanta's U.S. generic and specialty portfolio, weighted toward high-volume ophthalmic and dermatology lines where contract-pharmacy claim concentration and dispensing anomalies are most frequently observed — approximately 1.4% of estimated U.S. net revenue.
Industry Benchmarks
~5%
of non-Medicaid sales subject to a duplicate discount
1–3%
of total U.S. revenues lost to pharmacy fraud
Pharmaceutical manufacturers have built sophisticated capabilities around rebates, 340B, gross-to-net, and commercial operations. Yet today’s increasingly complex pharmacy ecosystem has created financial exposures that traditional transaction systems were never designed to detect.
The exposure isn’t a failure of your team. It’s a gap in what the systems were built to see.
Where Hidden Revenue Leakage Often Begins
Many manufacturers start by evaluating commercial and Medicare 340B duplicate discounts — one of the most measurable sources of unnecessary rebate expense. However, duplicate discounts are often just the first indicator of broader financial exposure. Organizations frequently uncover additional opportunities involving:
340B Duplicate Discounts
Where most engagements begin — and the most measurable.
Copay Card Fraud & Abuse
Program dollars redirected outside intended patient use.
Pharmacy Benefit Fraud
Claims activity that doesn't reconcile to legitimate dispensing.
Manufacturer Assistance Program Abuse
Assistance funds captured by parties they weren't built for.
Pharmacy Billing Anomalies
Patterns that clear transaction systems but don't hold up.
Inventory Diversion
Product moving outside authorized channels.
Suspicious Dispensing Behavior
Outlier prescriber and pharmacy behavior at the account level.
Emerging Pharmacy Fraud Schemes
New patterns before they become industry-wide losses.
Visual — Revenue Leakage Continuum
Duplicate
Discounts
Copay & Assistance Abuse
Benefit &
Billing Fraud
Diversion &
Dispensing
Emerging
Schemes
Where Hidden Revenue Leakage Often Begins
Many manufacturers start by evaluating commercial and Medicare 340B duplicate discounts, one of the most measurable sources of unnecessary rebate expense. Duplicate discounts are often just the first indicator of broader financial exposure. Organizations frequently uncover additional opportunities involving:
Wondering whether any of this applies to Ajanta Pharma USA Inc.?
That is the entire purpose of the first conversation.
Why CiiTA?
CiiTA occupies a unique position at the intersection of pharmaceutical finance, pharmacy operations, and revenue integrity. We focus exclusively on helping pharmaceutical manufacturers uncover hidden financial opportunities.
What Executive Teams Gain
- Greater financial visibility
- Improved gross-to-net performance
- Quantifiable revenue recovery opportunities
- Earlier identification of emerging financial risks
- Objective analysis that complements existing teams
- A clearer understanding of pharmacy-related revenue integrity
Sample Output
Highest-value asset for this page. A redacted screenshot of an actual CiiTA finding or Polaris output makes the offer concrete.
Illustration
Homepage-style line illustration. Suggested subject: executive reviewing results on a large display.
What the First Conversation Is Actually Like
Is this a sales pitch?
No. The first conversation is diagnostic. If there is no exposure worth pursuing, we will tell you that.
Do we have to share data to talk?
No data is required for the first conversation. Nothing is requested until you decide there's something worth measuring.
We already have teams on this.
Most manufacturers do. Our analysis complements internal teams rather than duplicating them, and looks where transaction systems were not designed to.
Start With A Conversation, Not A Sales Presentation
Our first discussion is confidential, collaborative, and focused on one question:
Could hidden pharmacy-related revenue leakage be affecting Ajanta Pharma USA Inc.?
If the answer is yes, we will help you understand where it exists, how it can be measured, and what opportunities may be available to improve financial performance.
Book A CallOpens the booking calendar in a new tab
- 30 minutes
- Confidential
- No data required to start
- No obligation
Pharmacy revenue integrity for pharmaceutical manufacturers.
Identify. Quantify. Prevent. Recover.
Connect
Copyright 2026 ciitainc.com. Created by Left Right Labs.
ZoomInfo tracking snippet loads here